Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells

被引:0
作者
Kun-zhong Zhang
Jian-hua Xu
Xiu-wang Huang
Li-xian Wu
Yu Su
Yuan-zhong Chen
机构
[1] Institute of Clinical Pharmacology,
[2] School of Pharmacy,undefined
[3] Fujian Medical University,undefined
[4] Fujian Institute ofHematology,undefined
来源
Acta Pharmacologica Sinica | 2007年 / 28卷
关键词
combination drug therapy; curcumin; abl genes; antisense oligonucleotides; chronic myelogenous leukemia; bcr-abl fusion proteins;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:105 / 110
页数:5
相关论文
共 69 条
[1]  
Ben-Neriah Y(1986)The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233 212-4
[2]  
Daley GQ(1985)Structural organization of the bcr gene and its role in the Ph1 translocation. Nature 315 758-61
[3]  
Mes-Masson AM(2000)The molecular biology of chronic myeloid leukemia. Blood 96 3343-56
[4]  
Witte ON(1999)Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol 78 49-64
[5]  
Baltimore D(2005)15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood 105 1750-8
[6]  
Heisterkamp N(2001)Cotreatment with STI-571 Enhances tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL or Apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 7 350-7
[7]  
Stam K(2001)Novel therapies for chronic myelogeous leukemia. Exp Hematol 29 543-56
[8]  
Groffen J(2002)Antigene effect in K562 cells of a PEG-conjugated triplexforming oligonucleotide targeted to the bcr/abl oncogene. Biochemistry 41 502-10
[9]  
Groffen J(2003)Anticancer potential of curcuma: preclinical and clinical studies. Anticancer Res 23 363-98
[10]  
de Klein A(2003)Inhibitory effect of curcumin on proliferation of K562 cells involves down-regulation of P210 Acta Pharmacol Sin 24 1155-60